Intrinsic expression of drug resistance-associated factors in meningiomas

Applied Immunohistochemistry and Molecular Morphology

Volumn 9, Issue 3, 2001, Pages 242-249

  Tews, D S ^a   Fleissner, C ^a   Tiziani, B ^a   Gaumann, A K A ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Chemotherapy; Drug resistance; Meningiomas; Recurrence,

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; GLYCOPROTEIN P; HYDROXYUREA; LUNG RESISTANCE PROTEIN; METALLOTHIONEIN; MULTIDRUG RESISTANCE PROTEIN; VINCRISTINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BRAIN TISSUE; CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; PRIORITY JOURNAL; TUMOR RECURRENCE; TUMOR RESISTANCE;

ADOLESCENT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM PROTEINS;

EID: 0034849120     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: 10.1097/00022744-200109000-00008     Document Type: Article

References (54)

1. Malignant transformation of recurrent meningioma with pulmonary metastases
2. Meningioma grading: An analysis of histologic parameters
3. Classic, atypical, and anaplastic meningioma: Three histopathologic subtypes of clinical relevance
4. Management of benign and aggressive intracranial meningiomas
5. Atypical and malignant meningiomas: An outcome report of seventeen cases
6. Intracranial meningiomas: Analysis of recurrence after surgical treatment
7. Primarily resected meningiomas: Outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988
8. Radiation therapy for intracranial meningiomas
9. Hydroxyurea for treatment of unresectable and recurrent meningiomas II. Decrease in the size of meningiomas in patients treated with hydroxyurea
10. In vitro chemotherapy of steroid receptor positive human meningioma low-passage primary cultures with nitrosourea-methionine-steroid conjugates
11. Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas
12. Adjuvant combined modality therapy for malignant meningiomas
13. Chemotherapy for meningiomas
14. The biochemistry of P-glycoprotein-mediated multidrug resistance
15. The drug resistance related protein LRP is a major vault protein
16. The human multidrug resistance-associated protein (MRP) is a plasma membrane drug efflux pump
17. Metallothionein in carcinogenesis and cancer chemotherapy
18. Overview of metallothionein
19. DNA topoisomerasetargeting antitumor agents and drug resistance
20. Transient induction of the MRP/GS-X pump and γ-glutamylcysteine synthetase by 1-(4amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3nitrosourea in human glioma cells
21. Studies of induction of metallothionein in Jar (human choriocarcinoma) cells by cis and trans isomers of diamminedichloroplatinum (II) and their hydrolyzed species
22. Drug resistance in brain tumors
23. Mechanisms of multidrug resistance in cancer treatment
24. The MDR superfamily of genes and its biologic implications
25. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport
26. Structure and expression of the messenger RNA encoding murine multidrug resistance protein, an ATP-binding cassette transporter
27. Multidrug resistance gene (MDR1) expression in human brain tumors
28. A study of the expression of four chemoresistance-related genes in human primary and metastatic brain tumors
29. P-glycoprotein expression in brain tumors
30. Ultrastructural localization of P-glycoprotein on capillary endothelial cells in human gliomas
31. MDR I P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas bit is not expressed in the neovasculature of other primary tumors
32. Expression of the multidrugresistance P-glycoprotein (Pgp, MDR1) by endothelial cells of the neovasculature in central nervous system tumors
33. Tissue distribution of the multidrug resistance protein
34. Lung resistance protein (LRP) expression in normal human tissues in comparison with that of MDR1 and MRP
35. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells
36. Possible involvement of multidrug-resistance-associated protein (MDR) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells
37. Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs
38. Distribution of metallothionein in the human central nervous system
39. Expression and regulation of brain metallothionein
40. Metallothionein in the human brain
41. Metallothionein overexpression in human brain tumors
42. Possible role for metallothionein in protection against radiation-induced oxidative stress. Kinetics and mechanisms of its reaction with superoxide and hydroxyl radicals
43. Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells
44. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells
45. T98G glioma cells have nicks in DNA quiescent phase
46. Gene specific damage and repair after treatment of cells with UV and chemotherapeutical agents
47. Elevated DNA topoisomerase activity in nitrogen mustard-resistant human cells
48. The multidrugresistance gene MDR1 is expressed in human glial tumors
49. Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells
50. P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier
51. Second malignant tumors following treatment during childhood and adolescence for cancer
52. Radiation-induced brain tumors: Potential late complications of radiation therapy for brain tumors
53. Investigation of chemoresistance-related genes mRNA expression for selecting anticancer agents in successful adjuvant chemotherapy for a case of recurrent glioblastoma